ResearcherUniversité de MontréalNo recent work listed

Maxime Parisotto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1987-7393; OpenAlex author ID A5032607005. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers14225597 ↗
Phenylethynylbenzyl-modified biguanides inhibit pancreatic cancer tumor growth. First author DOI 10.1038/s41598-021-87993-3 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Andreea R. Schmitzer · 2 shared papers, 2021–2022 · strength 0.27
- Paper The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells. DOI 10.3390/cancers14225597 ↗
- Paper Phenylethynylbenzyl-modified biguanides inhibit pancreatic cancer tumor growth. DOI 10.1038/s41598-021-87993-3 ↗
Gerardo Ferbeyre · 2 shared papers, 2021–2022 · strength 0.27
- Paper The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells. DOI 10.3390/cancers14225597 ↗
- Paper Phenylethynylbenzyl-modified biguanides inhibit pancreatic cancer tumor growth. DOI 10.1038/s41598-021-87993-3 ↗
Michaël Pollak · 1 shared paper, 2022 · strength 0.14
- Paper The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells. DOI 10.3390/cancers14225597 ↗
Audrey Hébert · 1 shared paper, 2021 · strength 0.13
- Paper Phenylethynylbenzyl-modified biguanides inhibit pancreatic cancer tumor growth. DOI 10.1038/s41598-021-87993-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.